Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2004)
21 slides from Resonance Health's shareholder meeting presentation, Nov 25, 2004
Slide 1: Annual General Meeting
resonance health limited | 20@ Annual General Meeting 25 November 2004 Alan Gilbert Building The University of Melbourne
Slide 2: Commercialising the FerriScan Technology: Investor Update
resonance health limited | 20@ Commercialising the Ferriscan™ Technology “The Future of Liver Diagnosis” Investor Update November 2004
Slide 3: Commercialising the FerriScan Technology
Commercialising the Ferriscan™ Technology “The Future of Liver Diagnosis” Resonance Health (ASX: RHT) - specialise in imaging technology. The FerriScan™ Technology is a novel, non-invasive 6 liver diagnostic with global applications developed by a multi-disciplinary team at The University of Western
Slide 4: What is the FerriScan Technology
What is the Ferriscan™ Technology « Asafe, non-invasive and accurate test to.m concentration ¢ Utilises existing MRI equipment, proprietary software anda patented iron “marker” known as “R2”. ¢ Provides clinicians around the world with a new and safe diagnostic tool to track liver iron levels in the
Slide 5: Liver Biopsy is the Current Gold Standard for Measuring Liver Iron
Liver Biopsy is the Current “Gold Standard” for Measuring Liver Iron onis made between the ribs anc a neectle is inserted in order to reach the area of the liver where.a tissue sample. is taken. The procedure requires a local anesthesia. Area where a tissue sample is taken from Bunctine site If an e
Slide 6: The FerriScan Test Process
The FerriScan™ Test Process MAI image transmitted IVE's Central image Analysis Centre Jest reports transmiites o walt resonance health limited
Slide 7: Why Test for Iron Overload?
Why Test for lron Overload? * Chronic disorders of iron metabolism are among diseases (1 in 200 for HHC). * The result is too much iron is absorbed by the digestive system and accumulates in the body (and in its largest organ — the liver). ¢ Iron overload has previously been difficult to detect and
Slide 8: Market Potential: FerriScan Iron Overload Application
Market Potential: FerriScan ™ / ron Overload Application * Iron loading disorders prevalence app ( developed world population. ¢ Australia: — 125,000 potential patients ° U.K: — 500,000 potential patients « U.S. > 4 million potential patients ¢ World market potential value for FerriScan™ service = >
Slide 9: Diseases Associated With Iron Overload
Diseases Associated With lron Overload ¢ Thalassaemia (minor & major) — Hereditary conditions prevalent in people of. Mediterranean des: parts of South East Asia. Thalassemia (major) is a-very severe debilitating form of anemia (typically a terminal illness). * Haemochromatosis — Ahereditary disease
Slide 10: Other Direct Applications for the FerriScan Technology Platform
Other Direct Applications for the Ferriscan™ Technology Platform e Hepatitis C — Assessment of liver iron levels to ensure the efficacy of prescrip: treatments (1 in 100 people in developed countries). e Adjunct to blood tests in the diagnosis of Hereditary Haemochromatosis (HHC) or to rule out iron
Slide 11: A Clear Choice
44 A Clear Choice FerriScan™ a) Non-invasive and painless b) Can be performed regularly if necessary c) No hospital stay d) Can be performed on infants and young children e) Cheaper and more efficient to administer f) Reduced liability to clinicians g) Results assessed at a central location in 24 —
Slide 12: Distribution Map - Iron Overload Disorders
Distribution Map -lron Overload Disorders IE Hemnglobinepathies [0 Haenochrometosis 4,000,000 10,000,000 resonance health limited 12
Slide 13: FerriScan / Iron Overload Application: USA & Australian Market Potential
Ferriscan™ / lron Overload Application USA & Australian Market Potential Total Australia. Population (USA & AUST) 289,000,000 20,000,000 Prevalence population, iron 2,125,000 425,000 : 2,000,000 overload. : Potential FerriScan™ test volume (@ 2 tests / pt / yr) 4,250,000 250,000 4,000,000 Potential
Slide 14: Growth in Current Diagnostic Tests for Iron Overload
14 Growth in Current Diagnostic Tests for lron Overload studies growth in A stralia_ : on binding ca cl fen Over.a five year conseculive period (1999-2003) financial years), the volume of blood iron studies performed.- increased by 92%, gene tests specific for — — ; haemochromatosis aemochromatosis
Slide 15: Available Globally - Processed Locally
16 Available Globally — Processed Locally MRI units can be enabled remotely to incorporate Technology and to perform the FerriScan™ Test (current enabled in USA, South America, Europe, The Middle Ea Australia) Liver Scans from the MRI (off-line) are sent via the Internet to the FerriScan™ Analysis C
Slide 16: Technology Achievements - To Date
16 ©) loner Vision Biometrics Pty Lid Technology Achievements - To Date | FerriScan™ US Patent Issued. Patents | lodged in. other territories. Trademark applied for Publication of the IVB-FerriScan™ Technology i in major peer revi international journals including “Blood” 45 MRI units have been enabl
Slide 17: Potential FerriScan Test Pricing
17 Potential Ferriscan™ Test Pricing Australia: FerriScan™ Test (revenue) $300 MRI Scan $300 Patient Cost (before reimbursement) $600 USA: (in AUD$) Ferriscan™ Test (revenue) $450 MRI Scan $600 Patient Cost (before reimbursement) $1,050 * Note: Pricing is indicative only at this stage resonance heal
Slide 18: Board of Directors
Board of Directors ¢ Hon. Dr Michael Wooldridge (Non- -Executive — Former Federal Minister for-Health ¢ Mr Tony Fitzgerald (Executive Director) — Legal and healthcare licensing expertise, 18 years experience in commercialising healthcare and biotech projects ¢ Dr Christine Bennett (Non-Executive Dir
Slide 19: Capital Structure
Capital Structure (As at 23 November 2004) Shares: Listed Shares on issue (RHT) — Market Capitalisation (at RHT Share price of $0.18) $15.6 M Options (exercise prices): RHTOA Options ($0.15 to 15 Jan 2007) 53,000,351 RHTOB Options ($0.40 to 15 Jan 2008) 12,066,152 Unlisted Directors options ($0.30 o
Slide 20: Major Progress Towards Commercialisation of FerriScan
Major Progress Towards Commercialisation of FerriScan™ 1. TGA Listing for Australia 2. Provides reciprocal access to Europe through CE Mark : 3. US FDA 510(k) to be submitted before end of 2004 4. Major radiology partner identified for initial Australian commercial roll-out, commencing December 2004
Slide 21: Forward looking statements and risks
This presentation contains forward-looking statemen 24 Forward looking statements and risks management’s current expectations. These statements m. materially from actual future events or results due to the range of risks" and uncertainties associated with the healthcare technology product developmen
Resonance Health — Shareholder Meeting (November 2004) on 6ix